MSD’s TROP2-targeting antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), has offered a significant overall survival (OS) benefit in another Phase III trial – adding a type of stomach cancer to its list of late-stage study successes. 

This win stems from the Phase III TroFuse-015 study (NCT06356311) evaluating the potential of the drug against a treatment of physician’s choice (TPC) in third-line-plus locally advanced unresectable or metastatic gastroesophageal adenocarcinoma (GEA). In this case, patients in the TPC arm received chemotherapy agents, trifluridine-tipiracil and irinotecan, plus paclitaxel or docetaxel. 

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

At final analysis, sac-TMT offered a significant and clinically meaningful improvement in OS over TPC, with the results proving generally consistent and independent of whether a patient expressed TROP2 or not. However, the drug did not have a significant impact on progression-free survival (PFS) – missing the trial’s secondary endpoint. 

In terms of objective patient responses, the ADC did show a numerical benefit over TPC, though researchers did not formally test this under TroFuse-015’s prespecified analysis plan. 

Meanwhile, patients tolerated sac-TMT well, with investigators identifying no new safety signals in the study. 

The TroFuse-015 win comes a little after sac-TMT met its endpoints in the Phase III TroFuse-005 trial (NCT06132958), which is exploring the drug’s promise in endometrial cancer. These results expand the drug’s potential market reach as MSD runs the widest development programme for any TROP2-targeting ADC in pharma – evaluating the drug’s prospects across several solid tumour indications such as breast, lung, bladder and gynaecological cancers, to name a few. 

MSD, known in the US as Merck & Co, originally acquired the rights outside of Greater China to sac-TMT from the drug’s developer, Kelun-Biotech, which has also secured some milestones for the drug.  

At the 2026 European Society for Medical Oncology (ESMO) congress, Professor Wenfeng Fang presented data from the OptiTROP-Lung04 study (NCT05870319), which revealed that sac-TMT extended OS to 25.9 months versus 17.4 months in the comparator arm in Chinese patients with EGFR-mutated, non-squamous non-small cell lung cancer (NSCLC). 

On top of this, the company has also secured Chinese approval for sac-TMT in four indications, with three more currently under review by China’s National Medical Products Administration (NMPA). The agency has already greenlit sac-TMT, marketed in China as Giatelai, for use in certain types of breast and lung cancers, as well as cancers that are unresectable or metastatic and both HR-positive and HER2-negative.  

According to GlobalData’s Pharmaceutical Intelligence Center, sac-TMT will hit blockbuster status in 2030, before reaching sales of $3.6bn in 2032 at the end of the forecast period. 

GlobalData is the parent company of Clinical Trials Arena.